Olumiant® ▼ (baricitinib)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Olumiant Summary of Product Characteristics (SmPC)

Olumiant®▼ (baricitinib): Incidence of Demyelinating Disorders in the RA Clinical Development Program

Demyelinating disorders are not listed in the baricitinib approved prescribing information as adverse drug reactions in RA patients.

Description of the All BARI RA Dataset

The All BARI RA safety dataset includes patients with RA (N=3770, PYE=13,148, median exposure=4.2 yrs, maximum exposure=8.4 yrs) from 1 phase 1, 3 phase 2, 5 phase 3 studies, and 1 phase 3 extension study who received BARI at a variety of doses, including

  • BARI 4 mg (n=3400)

  • BARI 2 mg (n=1077), and

  • BARI 1 mg, 7 mg, 8 mg, and 10 mg QD doses not evaluated in confirmatory studies.1

Patients had to have received at least 1 dose of BARI and could have received different doses throughout the trials. Evaluation time period is all exposure time points including after rescue or changes in study drug through 01 September 2019.1

Incidence of Demyelinating Disorders in the All BARI RA Dataset

Identification of demyelinating disorders in the BARI clinical program was based on the SMQ 20000154 narrow PTs. For a listing of the narrow PTs, see Table 1.

In the All BARI RA safety dataset, there was 1 TEAE of hypergammaglobulinaemia benign monoclonal, which occurred in the 2-mg treatment group. The EAIR based on the 1 confirmed case is 0.00 per 100 PYE.2

The single TEAE hypergammaglobulinaemia was of mild severity, not serious, not related to study drug, and did not cause study drug discontinuation.2

The broad search of terms that was completed resulted in no cases of multiple sclerosis.2

Table 1. Standardized MedDRA Demyelination Query (SMQ) 20000154 Narrow Preferred Terms2

Acute disseminated encephalomyelitis

Marchiafava-Bignami disease

Acute haemorrhagic leukoencephalitis

Multiple sclerosis

Anti-myelin –associated glycoprotein associated polyneuropathy

Multiple sclerosis relapse

Autoimmune demyelinating disease

Multiple sclerosis relapse prophylaxis

Chronic inflammatory demyelinating polyradiculoneuropathy

Myelitis transverse

Clinically isolated syndrome

Myoclonic epilepsy and ragged-red fibres

Concentric sclerosis

Neuromyelitis optica spectrum disorder

Demyelinating polyneuropathy

Neuropathy, ataxia, retinitis pigmentosa syndrome

Demyelination

Noninfectious myelitis

Encephalitis periaxialis diffusa

Noninfective encephalomyelitis

Encephalomyelitis

Optic neuritis

Expanded disability status scale score decreased

Osmotic demyelination syndrome

Expanded disability status scale score increased

Primary progressive multiple sclerosis

Guillain-Barre syndrome

Progressive multifocal leukoencephalopathy

Hypergammaglobulinaemia benign monoclonal

Progressive multiple sclerosis

Leukoencephalomyelitis

Progressive relapsing multiple sclerosis

Leukoencephalopathy

Relapsing-remitting multiple sclerosis

Lewis-Summer syndrome

Secondary progressive multiple sclerosis

MELAS syndrome

Toxic leukoencephalopathy

Marburg’s variant multiple sclerosis

Tumefactive multiple sclerosis

Abbreviations: MedDRA = Medical Dictionary for Regulatory Activities; SMQ = standardized MedDRA query.

References

1. Genovese MC, Smolen JS, Takeuchi T, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 8.4 years: an updated integrated safety analysis [abstract]. Ann Rheum Dis. 2020;79(suppl 1):638. http://scientific.sparx-ip.net/archiveeular/?c=a&view=4&item=2020FRI0123

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Glossary

BARI = baricitinib

EAIR = exposure-adjusted incidence rate

MedDRA = Medical Dictionary for Regulatory Activities

PT = preferred term

PYE = patient-years of exposure

QD = daily

RA = rheumatoid arthritis

SMQ = standardized MedDRA query

TEAE = treatment-emergent adverse event

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: January 01, 2020


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question